Medizinische Universität Graz - Research portal
Selected Publication:
Geraldy,P.
Susceptibility of carbapenem-resistant Pseudomonas aeruginosa clinical isolates to novel cephalosporin antibiotics
Humanmedizin; [Diplomarbeit] Medical University of Graz;2019. pp.49
[OPEN ACCESS]
FullText
- Authors Med Uni Graz:
- Advisor:
- Zollner-Schwetz Ines
- Altmetrics:
- Abstract:
- Background: Carbapenems are important antimicrobials for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa. Alarming numbers of carbapenem-resistant Pseudomonas isolates are found worldwide but also locally at the Microbiology Laboratory, Dept. of Internal Medicine, Medical University of Graz. Three novel antimicrobial cephalosporin agents (ceftolozane/tazobactam, ceftazidime/avibactam and ceftobiprole) have been introduced for the treatment of Pseudomonas infections. We tested the susceptibility of carbapenem-resistant P. aeruginosa clinical isolates to these antimicrobial agents. Materials/Methods: 60 carbapenem-resistant P. aeruginosa clinical isolates were identified. MIC (minimal inhibitory concentration) was determined using gradient strip tests (BioMérieux) using standard procedures according to EUCAST, carbapenemase-activity was detected by using Rapidec® Carba testing kits and MBL activity was detected by using E-test strips. Results: 80.0% (48/60) of carbapenem-resistant P. aeruginosa isolates were susceptible to ceftolozane/tazobactam (MIC50 = 4 mg/l). 71.7% (43/60) were susceptible to ceftazidime/avibactam (MIC50 = 4 mg/l). In comparison, 66.7% (40/60) were susceptible to ceftazidime alone (MIC50 = 4 mg/l). 25.0% (15/60) were susceptible to ceftobiprole using PK/PD breakpoints (MIC50 = 32 mg/l). 22.0% (13/59) of the tested P. aeruginosa isolates expressed MBL-activity. Conclusions: The novel cephalosporin combinations ceftolozane/tazobactam and ceftazidime/avibactam appear to be a promising treatment option in carbapenem-resistant P. aeruginosa.